Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer
Language English Country Czech Republic Media print-electronic
Document type Journal Article
Grant support
0064190
Ministerstvo Zdravotnictví Ceské Republiky
PubMed
31431233
DOI
10.14712/18059694.2019.129
PII: 18059694.2019.129
Knihovny.cz E-resources
- Keywords
- antitumor immunity, colorectal cancer, vascular endothelial growth factor inhibition,
- MeSH
- Immunotherapy * methods MeSH
- Colorectal Neoplasms immunology therapy MeSH
- Humans MeSH
- Tumor Microenvironment immunology MeSH
- Vascular Endothelial Growth Factors antagonists & inhibitors MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Vascular Endothelial Growth Factors MeSH
There is a growing corpus of evidence indicating that anti-VEGF therapy may normalize the abnormal tumor vasculature with the potential to re-program the tumor immune microenvironment to a more immunosupportive profile. Tumor vessel normalization increases tumor perfusion, and, consequently, oxygen and nutrient supply, and thus can be assumed to improve the general response to anticancer immunotherapy. The increased antitumor immunity responses seen following anti-VEGF therapy may also be associated with the inhibition of the immunosuppressive action deployed by VEGF on effector T cells. Bearing in mind the recent advances of combination immunotherapy, combinations of anti-VEGF therapy with immune checkpoint inhibitors now appear to represent an attractive strategy. Key to the successful implementation of a combination strategy for treating cancer is understanding the interaction of these two therapeutic interventions, particularly in regards to appropriate reprogramming of the tumor immune microenvironment to improve antitumor immunity.
References provided by Crossref.org
